<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04811222</url>
  </required_header>
  <id_info>
    <org_study_id>20-5802</org_study_id>
    <nct_id>NCT04811222</nct_id>
  </id_info>
  <brief_title>DOTATATE PETMRI AAA Study</brief_title>
  <official_title>Gallium-DOTATATE PET-MR Imaging to Detect Macrophages in Abdominal Aortic Aneurysms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Abdominal Aortic Aneurysm (AAA) screening and an aging population have increased the&#xD;
      prevalence of AAA diagnoses. Small AAAs (&lt;5.5cm) are monitored with ultrasound. Large AAAs&#xD;
      may rupture and this is usually fatal. Surgery is considered at a crude size threshold of&#xD;
      5.5cm when the annual rupture risk reaches 5%. AAA size is the only predictor of growth and&#xD;
      rupture available but growth is non-linear and some small AAAs rupture. Thus, only 1 in 20&#xD;
      patients treated at 5.5cm will have benefited from rupture prevention in the year following&#xD;
      surgery, and others may miss out on life-saving surgery. This study will develop an imaging&#xD;
      tool PETMRI with radiotracer Ga- DOTATATE with high clinical utility, to improve prediction&#xD;
      of aneurysm growth and risk.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prevalence of abdominal aortic aneurysm (AAA) in those over 65 years is 4-8% and rising.&#xD;
      Currently, AAA size is the only metric to determine risk of growth/rupture; we are unable to&#xD;
      image the underlying disease process. Using size alone is problematic. For small AAAs there&#xD;
      is no consensus between surgical societies on appropriate surveillance intervals. AAA growth&#xD;
      is non-linear and thus some small AAAs may rupture between screening intervals.&#xD;
&#xD;
      Macrophage mediated inflammation leads to weakening of the aortic wall. Our own laboratory&#xD;
      work indicates macrophages correlate with AAA severity in mice. In humans, activated&#xD;
      macrophages express SomatoSTatin Receptor 2 (SSTR2). For the first time ever, using a&#xD;
      radiotracer probe specific for SSTR 2 (gallium-dotatate), we will detect activated&#xD;
      macrophages in AAAs using Positron Emission Tomography- Magnetic Resonance Imaging (PET-MRI).&#xD;
      Patients attending the University Health Network (UHN) Vascular clinic undergoing ultrasound&#xD;
      surveillance of small AAAs of differing sizes will be imaged with Ga-Dotatate PET-MRI. We&#xD;
      will correlate aneurysm size and anatomical information with in-vivo imaging of aortic&#xD;
      macrophages detected with Ga-Dotatate, to determine the risk of aneurysm growth.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Ga-DOTATATE PETMRI scan</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>68-Ga DOTATATE uptake</measure>
    <time_frame>within 6 months after obtaining consent</time_frame>
    <description>Measuring AAA patient's 68-Ga DOTATATE uptake using PET/MRI as a marker of macrophage accumulation</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Abdominal Aortic Aneurysm</condition>
  <arm_group>
    <arm_group_label>Ga-DOTATATE PET/MRI scan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with abdominal aortic aneurysm will undergo Ga-DOTATATE PET/MRI scan</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Ga-DOTATATE PETMRI scan</intervention_name>
    <description>Patients with AAA with minimum 2 years surveillance will have one time Ga-DOTATATE PETMRI scan</description>
    <arm_group_label>Ga-DOTATATE PET/MRI scan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of asymptomatic abdominal aortic aneurysm AAA &gt;3cm in maximum diameter;&#xD;
&#xD;
          2. Minimum 2 years prior ultrasound or CT imaging of their AAA;&#xD;
&#xD;
          3. No prior treatment for AAA;&#xD;
&#xD;
          4. Age &gt;50 years;&#xD;
&#xD;
          5. No contraindications to PET/MRI, such as claustrophobia;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant females. All women of child-bearing potential must receive a negative urine&#xD;
             pregnancy test prior to administration of 68Ga-DOTATATE;&#xD;
&#xD;
          2. Allergy and/or hypersensitivity to MRI contrast agents (gadolinium) or components of&#xD;
             68Ga-DOTATATE drug product (as listed in IB);&#xD;
&#xD;
          3. Presence of pacemaker or implanted cardioverter defibrillator (ICD);&#xD;
&#xD;
          4. History of alcohol or substance abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Veit-Haibach</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Iris Zhong</last_name>
    <phone>416-946-4501</phone>
    <phone_ext>4816</phone_ext>
    <email>iris.zhong@uhn.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iris Zhong</last_name>
      <phone>416-946-4501</phone>
      <phone_ext>4816</phone_ext>
      <email>iris.zhong@uhn.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 10, 2021</study_first_submitted>
  <study_first_submitted_qc>March 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2021</study_first_posted>
  <last_update_submitted>March 19, 2021</last_update_submitted>
  <last_update_submitted_qc>March 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm, Abdominal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

